Braveheart Bio, Inc.

What they do

Braveheart Bio is developing BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor, for obstructive and non-obstructive hypertrophic cardiomyopathy. The company holds exclusive worldwide development and commercialization rights to BHB-1893 excluding Mainland China, Hong Kong, Macau and Taiwan under a license agreement with Jiangsu Hengrui Pharmaceuticals. It has initiated the Phase 3 LIONHEART-HCM trial in oHCM and plans a Phase 3 nHCM trial. Since inception it has devoted resources to organizing, hiring, acquiring rights to BHB-1893 and conducting R&D, with no product sales.

Revenue drivers

• Product sales — Braveheart Bio has no products approved for sale and has not generated any revenue from product sales.

Recent performance

For the three months ended June 30, 2026, research and development expenses were $11.1 million versus $0.0 million for the same period in 2025, driven by advancement of BHB-1893. Net loss for the six months ended June 30, 2026 was $29.3 million, compared to $0.5 million for the six months ended June 30, 2025. Cash and cash equivalents were $122.8 million as of June 30, 2026, up from $89.2 million as of December 31, 2025. The June 30, 2026 cash balance does not include IPO net proceeds of approximately $404.5 million, which would have brought cash to approximately $527.3 million on an as-adjusted basis.

Strategy

Braveheart Bio's stated goal is to advance BHB-1893 through global Phase 3 development in both oHCM and nHCM. The company initiated the Phase 3 LIONHEART-HCM trial comparing BHB-1893 to metoprolol in symptomatic oHCM, with sites being activated and patients screening, and expects to dose the first patient this year. It plans to initiate the Phase 3 NOBLEHEART-HCM trial in nHCM in the first half of 2027 and now has an active U.S. IND for that program. Management expects an interim analysis from LIONHEART-HCM in the second half of 2027. The company also completed a Series A third closing in April 2026 and an IPO in August 2026 to fund these efforts.

Risks

• No approved products or revenue — Braveheart Bio has no products approved for sale, has never generated product revenue, and may never achieve profitability.
• Clinical trial risk — BHB-1893 is in Phase 3 development and may fail to demonstrate sufficient efficacy or safety, including in the ongoing LIONHEART-HCM trial.
• Dependence on third-party license — The company relies on an exclusive license from Jiangsu Hengrui Pharmaceuticals for BHB-1893, and rights are limited to territories excluding Mainland China, Hong Kong, Macau and Taiwan.
• Significant and increasing expenses — Braveheart Bio expects to continue incurring significant and increasing expenses and substantial losses as it funds global Phase 3 trials in two indications.

Outlook

Management states that its existing cash and cash equivalents, together with IPO net proceeds, are expected to fund projected operating expenses and capital expenditure requirements into 2029. In oHCM, the Phase 3 LIONHEART-HCM trial is underway, with first patient dosing expected this year and interim analysis results expected in the second half of 2027. In nHCM, the company expects to initiate the global Phase 3 NOBLEHEART-HCM trial in the first half of 2027, supported by an active U.S. IND.